ORYZON GENOMICS, S.A. «12345...» Page 2 out of 11 from 01/07/1988 to 11/05/2024 The price-sensitive information presented in other languages is a literal translation of the price-sensitive information stated in Spanish 16/07/2019 09:05 ORYZON GENOMICS, S.A. R&D: new licenses, patents and registered trademarks ORYZON announces that data from its ETHERAL Phase IIa clinical trial of vafidemstat in Alzheimer’s patients were presented yesterday at the Alzheimer´s Association International Conference (AAIC-2019) Register number: 280225 14/06/2019 07:35 ORYZON GENOMICS, S.A. R&D: new licenses, patents and registered trademarks Oryzon presents iadademstat preliminary efficacy data from the ALICE Phase IIa trial in acute myeloid leukemia Register number: 279154 17/05/2019 13:32 ORYZON GENOMICS, S.A. Announcements and resolutions of general shareholders meetings Oryzon Genomics, S.A. informs about the resolutions passed by the Ordinary General Shareholders’ Meeting. Register number: 278353 Related with 276934 of 09/04/2019 (07:45) 13/05/2019 14:49 ORYZON GENOMICS, S.A. Interim financial information La sociedad remite información sobre los resultados del primer trimestre de 2019 Register number: 278170 25/04/2019 06:28 ORYZON GENOMICS, S.A. R&D: new licenses, patents and registered trademarks Oryzon presents vafidemstat efficacy data from the REIMAGINE Phase IIa trial’s Attention Deficit Hyperactivity Disorder (ADHD) cohort Register number: 277371 09/04/2019 07:45 ORYZON GENOMICS, S.A. Announcements and resolutions of general shareholders meetings Call of the Ordinary General Shareholders’ Meeting of Oryzon Genomics, S.A. Register number: 276934 Related with 278353 of 17/05/2019 (13:32) 08/04/2019 07:06 ORYZON GENOMICS, S.A. R&D: new licenses, patents and registered trademarks Oryzon presents vafidemstat efficacy data from the REIMAGINE Phase II trial’s Borderline Personality Disorder cohort at the 27th European Congress of Psychiatry (EPA 2019) Register number: 276888 20/03/2019 08:07 ORYZON GENOMICS, S.A. R&D: new licenses, patents and registered trademarks Oryzon to present topline preliminary results on Vafidemstat’s Reimagine Phase IIa trial on the cohort of Borderline Personality Disorder Register number: 276239 11/03/2019 07:12 ORYZON GENOMICS, S.A. R&D: new licenses, patents and registered trademarks Approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug application (IND) for ETHERAL, a PhIIa clinical trial of vafidemstat (ORY-2001) Register number: 275854 15/02/2019 16:57 ORYZON GENOMICS, S.A. Board of directors remuneration annual statement La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del Ejercicio 2018 Register number: 274764 Page 2 out of 11 «12345...»